55
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Noonan syndrome-causing genes: Molecular update and an assessment of the mutation rate

      review-article
      a , b , , a , a , b , b , a , a , c , a
      International Journal of Pediatrics & Adolescent Medicine
      King Faisal Specialist Hospital and Research Centre
      Molecular etiology, MAP kinase signaling pathways, Mutation rate, Noonan syndrome, PTPN11, RAS family, CDC25, cell division cycle 25, CHD, congenital heart defects, CR, conserved region, CRD, cysteine-rich domain, GAP, GTPase activating protein, GDP, guanosine-DiPhosphate, GEF, guanine exchange factor, GTP, guanosine-TriPhosphate, GH, growth hormone, HCM, hypertrophic cardiomyopathy, IGF-1, insulin-like growth factor I, RBD, RAS binding domain, REM, RAS exchange motif

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Noonan syndrome is a common autosomal dominant disorder characterized by short stature, congenital heart disease and facial dysmorphia with an incidence of 1/1000 to 2500 live births. Up to now, several genes have been proven to be involved in the disturbance of the transduction signal through the RAS-MAP Kinase pathway and the manifestation of Noonan syndrome. The first gene described was PTPN11, followed by SOS1, RAF1, KRAS, BRAF, NRAS, MAP2K1, and RIT1, and recently SOS2, LZTR1, and A2ML1, among others. Progressively, the physiopathology and molecular etiology of most signs of Noonan syndrome have been demonstrated, and inheritance patterns as well as genetic counseling have been established. In this review, we summarize the data concerning clinical features frequently observed in Noonan syndrome, and then, we describe the molecular etiology as well as the physiopathology of most Noonan syndrome-causing genes. In the second part of this review, we assess the mutational rate of Noonan syndrome-causing genes reported up to now in most screening studies. This review should give clinicians as well as geneticists a full view of the molecular aspects of Noonan syndrome and the authentic prevalence of the mutational events of its causing-genes. It will also facilitate laying the groundwork for future molecular diagnosis research, and the development of novel treatment strategies.

          Related collections

          Most cited references100

          • Record: found
          • Abstract: found
          • Article: not found

          Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

          Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy). Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diatheses also are frequently associated with this disease. This syndrome is relatively common, with an estimated incidence of 1 in 1,000-2,500 live births. It has been mapped to a 5-cM region (NS1) [corrected] on chromosome 12q24.1, and genetic heterogeneity has also been documented. Here we show that missense mutations in PTPN11 (MIM 176876)-a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homology 2 (SH2) domains-cause Noonan syndrome and account for more than 50% of the cases that we examined. All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations. An energetics-based structural analysis of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equilibrium favoring the active conformation. This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

            Src homology-2 (SH2) domain-containing phosphatases (Shps) are a small, highly conserved subfamily of protein-tyrosine phosphatases, members of which are present in both vertebrates and invertebrates. The mechanism of regulation of Shps by ligand binding is now well understood. Much is also known about the normal signaling pathways regulated by each Shp and the consequences of Shp deficiency. Recent studies have identified mutations in human Shp2 as the cause of the inherited disorder Noonan syndrome. Shp2 mutations might also contribute to the pathogenesis of some leukemias. In addition, Shp2 might be a key virulence determinant for the important human pathogen Helicobacter pylori. Despite these efforts, however, the key targets of each Shp have remained elusive. Identifying these substrates remains a major challenge for future research.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Crystal structure of the tyrosine phosphatase SHP-2.

              The structure of the SHP-2 tyrosine phosphatase, determined at 2.0 angstroms resolution, shows how its catalytic activity is regulated by its two SH2 domains. In the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain binds the phosphatase domain and directly blocks its active site. This interaction alters the structure of the N-SH2 domain, disrupting its phosphopeptide-binding cleft. Conversely, interaction of the N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface. Thus, the N-SH2 domain is a conformational switch; it either binds and inhibits the phosphatase, or it binds phosphoproteins and activates the enzyme. Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation.
                Bookmark

                Author and article information

                Contributors
                Journal
                Int J Pediatr Adolesc Med
                Int J Pediatr Adolesc Med
                International Journal of Pediatrics & Adolescent Medicine
                King Faisal Specialist Hospital and Research Centre
                2352-6467
                18 August 2016
                December 2016
                18 August 2016
                : 3
                : 4
                : 133-142
                Affiliations
                [a ]Medical Genetics and Oncogenetics Laboratory, HASSAN II University Hospital, BP 1835, Atlas, Fez 30000, Morocco
                [b ]Laboratory of Microbial Biotechnology, Faculty of Sciences and Techniques, University of Sidi Mohammed Ben Abdellah, B.P. 2202, Route d'Imouzzer, Fez 30000, Morocco
                [c ]Medico-Surgical Unit of Cardio-pediatrics, Department of Pediatrics, HASSAN II University Hospital, BP 1835, Atlas, Fez 30000, Morocco
                Author notes
                []Corresponding author. Medical Genetics and Oncogenetics Unit, Hassan II University Hospital, Fez 30000, Morocco. Tel.:(+212) 610 36 75 09. ihssane.elbouchikhi@ 123456usmba.ac.ma
                Article
                S2352-6467(16)30032-1
                10.1016/j.ijpam.2016.06.003
                6372459
                30805484
                086ec2d2-a989-410f-aaba-9af532be6e01
                © 2016, King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. Production and hosting by Elsevier B.V.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 15 April 2016
                : 14 June 2016
                Categories
                Review

                molecular etiology,map kinase signaling pathways,mutation rate,noonan syndrome,ptpn11,ras family,cdc25, cell division cycle 25,chd, congenital heart defects,cr, conserved region,crd, cysteine-rich domain,gap, gtpase activating protein,gdp, guanosine-diphosphate,gef, guanine exchange factor,gtp, guanosine-triphosphate,gh, growth hormone,hcm, hypertrophic cardiomyopathy,igf-1, insulin-like growth factor i,rbd, ras binding domain,rem, ras exchange motif

                Comments

                Comment on this article